MX2019003470A - Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. - Google Patents

Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.

Info

Publication number
MX2019003470A
MX2019003470A MX2019003470A MX2019003470A MX2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical composition
liver disease
fatty liver
alcoholic fatty
Prior art date
Application number
MX2019003470A
Other languages
English (en)
Inventor
P Cooreman Michael
Kikkawa Kohei
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2019003470A publication Critical patent/MX2019003470A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invencion proporciona una composicion farmaceutica para la profilaxis y el tratamiento de la EHGNA que comprende como un ingrediente activo un compuesto de 1,4- benzoxazina representado por la formula (I): o una sal farmaceuticamente aceptable del mismo, y un vehiculo farmaceuticamente aceptable, asi como un metodo para la profilaxis y el tratamiento de la EHGNA el cual comprende administrar una cantidad terapeuticamente eficaz del compuesto de 1,4-benzoxazina mencionado anteriormente representado por la formula (I) y demas a un paciente en necesidad del mismo.
MX2019003470A 2016-09-27 2017-09-26 Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. MX2019003470A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400200P 2016-09-27 2016-09-27
PCT/JP2017/034654 WO2018062134A1 (en) 2016-09-27 2017-09-26 Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2019003470A true MX2019003470A (es) 2019-08-29

Family

ID=60083378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003470A MX2019003470A (es) 2016-09-27 2017-09-26 Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.

Country Status (16)

Country Link
US (1) US11285160B2 (es)
EP (1) EP3518936B1 (es)
JP (1) JP6980008B2 (es)
KR (1) KR20190061027A (es)
CN (2) CN114984021A (es)
AU (1) AU2017338161A1 (es)
BR (1) BR112019005456A2 (es)
CA (1) CA3038247A1 (es)
CO (1) CO2019004004A2 (es)
ES (1) ES2840079T3 (es)
IL (1) IL265292A (es)
MX (1) MX2019003470A (es)
PH (1) PH12019500618A1 (es)
RU (1) RU2019112148A (es)
TW (1) TW201817425A (es)
WO (1) WO2018062134A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102162921B1 (ko) * 2018-11-28 2020-10-07 건양대학교 산학협력단 니페디핀 함유 나노입자를 포함하는 지방간 질환 및 인슐린 저항성 예방 또는 치료용 조성물
TW202045184A (zh) 2019-02-05 2020-12-16 日商田邊三菱製藥股份有限公司 預防或治療肺纖維化的藥物
WO2021107029A1 (ja) * 2019-11-26 2021-06-03 田辺三菱製薬株式会社 ヒトの非アルコール性脂肪肝炎の予防薬または治療薬
WO2023101441A1 (ko) * 2021-11-30 2023-06-08 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4509395B2 (ja) * 1999-04-27 2010-07-21 田辺三菱製薬株式会社 肝臓疾患の予防治療薬
CN101379048B (zh) * 2006-02-02 2012-03-21 田边三菱制药株式会社 可用作盐皮质激素受体调节试剂的苯并*嗪和相关的含氮杂双环化合物
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
US8258131B2 (en) * 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
WO2011118976A2 (en) * 2010-03-24 2011-09-29 Dong-A Pharm. Co., Ltd. Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
EP3112354B1 (en) * 2012-08-08 2018-07-25 Mitsubishi Tanabe Pharma Corporation Method for producing 1,4-benzoxazine compound

Also Published As

Publication number Publication date
BR112019005456A2 (pt) 2019-06-04
CN114984021A (zh) 2022-09-02
JP6980008B2 (ja) 2021-12-15
CO2019004004A2 (es) 2019-07-31
ES2840079T3 (es) 2021-07-06
PH12019500618A1 (en) 2019-11-18
AU2017338161A1 (en) 2019-04-18
US11285160B2 (en) 2022-03-29
WO2018062134A1 (en) 2018-04-05
CN109789147A (zh) 2019-05-21
IL265292A (en) 2019-05-30
CN109789147B (zh) 2022-06-24
TW201817425A (zh) 2018-05-16
US20210290627A1 (en) 2021-09-23
RU2019112148A3 (es) 2021-01-15
EP3518936B1 (en) 2020-11-18
EP3518936A1 (en) 2019-08-07
CA3038247A1 (en) 2018-04-05
JP2019529477A (ja) 2019-10-17
KR20190061027A (ko) 2019-06-04
RU2019112148A (ru) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
PH12020550341A1 (en) Niraparib formulations
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TN2016000491A1 (en) Carboxamide derivatives.
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12015501945B1 (en) Formulations of organic compounds
SG10201907289VA (en) Monomethylfumarate prodrug compositions
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
PH12020551620A1 (en) Compositions for preventing or treating dry eye
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2